Evolus, Inc. Completes Its Acquisition by Strathspey Crown Holdings, LLC

Evolus, Inc.

Represented Evolus, Inc. in its acquisition by Strathspey Crown Holdings LLC. Read the press release.

As part of the transaction, Strathspey Crown's wholly-owned subsidiary, ALPHAEON Corporation, received the exclusive license to market, in both the U.S. and several international markets, an advanced Botulinum toxin Type A neurotoxin developed by Daewoong Pharmaceutical Co.

Evolus, Inc. manufactures clinical neurotoxins used in cosmetic surgery.